{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T15:02:16Z","timestamp":1771340536093,"version":"3.50.1"},"reference-count":102,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["19EIA34760167"],"award-info":[{"award-number":["19EIA34760167"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1K99HL140139-01A1"],"award-info":[{"award-number":["1K99HL140139-01A1"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R01HL130301-01;1R01HL147639-01A1;"],"award-info":[{"award-number":["1R01HL130301-01;1R01HL147639-01A1;"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Lipodystrophy is a disease characterized by a partial or total absence of adipose tissue leading to severe metabolic derangements including marked insulin resistance, type 2 diabetes, hypertriglyceridemia, and steatohepatitis. Lipodystrophy is also a source of major cardiovascular disorders which, in addition to hepatic failure and infection, contribute to a significant reduction in life expectancy. Metreleptin, the synthetic analog of the adipocyte-derived hormone leptin and current therapy of choice for patients with lipodystrophy, successfully improves metabolic function. However, while leptin has been associated with hypertension, vascular diseases, and inflammation in the context of obesity, it remains unknown whether its daily administration could further impair cardiovascular function in patients with lipodystrophy. The goal of this short review is to describe the cardiovascular phenotype of patients with lipodystrophy, speculate on the etiology of the disorders, and discuss how the use of murine models of lipodystrophy could be beneficial to address the question of the contribution of leptin to lipodystrophy-associated cardiovascular disease.<\/ns4:p>","DOI":"10.12688\/f1000research.20150.1","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T09:35:39Z","timestamp":1571218539000},"page":"1756","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function"],"prefix":"10.12688","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5671-318X","authenticated-orcid":false,"given":"Thiago","family":"Bruder-Nascimento","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor C.","family":"Kress","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0184-3830","authenticated-orcid":false,"given":"Eric J.","family":"Belin de Chantemele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"137-50","DOI":"10.1038\/nrendo.2010.199","article-title":"Lipodystrophy: pathophysiology and advances in treatment.","volume":"7","author":"C Fiorenza","year":"2011","journal-title":"Nat Rev Endocrinol."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3390\/genes10050342","article-title":"Congenital Leptin Deficiency and Leptin Gene Missense Mutation Found in Two Colombian Sisters with Severe Obesity.","volume":"10","author":"H Yupanqui-Lozno","year":"2019","journal-title":"Genes (Basel)."},{"key":"ref-3","first-page":"13-4","article-title":"Metreleptin (Myalept): a leptin analog for generalized lipodystrophy.","volume":"57","year":"2015","journal-title":"Med Lett Drugs Ther."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"1802-10","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.","volume":"100","author":"T Diker-Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"3313-25","DOI":"10.1210\/jc.2011-1159","article-title":"Clinical review#: Lipodystrophies: genetic and acquired body fat disorders.","volume":"96","author":"A Garg","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"1433-44","DOI":"10.1194\/jlr.R700004-JLR200","article-title":"Thematic review series: Adipocyte Biology. Lipodystrophies: windows on adipose biology and metabolism.","volume":"48","author":"R Hegele","year":"2007","journal-title":"J Lipid Res."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"570-8","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy.","volume":"346","author":"E Oral","year":"2002","journal-title":"N Engl J Med."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"522-34","DOI":"10.1038\/nrendo.2015.123","article-title":"Congenital generalized lipodystrophies--new insights into metabolic dysfunction.","volume":"11","author":"N Patni","year":"2015","journal-title":"Nat Rev Endocrinol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"365-70","DOI":"10.1038\/ng585","article-title":"Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13.","volume":"28","author":"J Magr\u00e9","year":"2001","journal-title":"Nat Genet."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1129-34","DOI":"10.1210\/jc.2007-1328","article-title":"Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy.","volume":"93","author":"C Kim","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"2623-33","DOI":"10.1172\/JCI38660","article-title":"Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy.","volume":"119","author":"Y Hayashi","year":"2009","journal-title":"J Clin Invest."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"21-3","DOI":"10.1038\/ng880","article-title":"AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.","volume":"31","author":"A Agarwal","year":"2002","journal-title":"Nat Genet."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"451-9","DOI":"10.1002\/1098-1004(200012)16:6<451::AID-HUMU1>3.0.CO;2-9","article-title":"Mutations in the LMNA gene encoding lamin A\/C.","volume":"16","author":"J Genschel","year":"2000","journal-title":"Hum Mutat."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"922-32","DOI":"10.4158\/EP11229.OR","article-title":"Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.","volume":"17","author":"J Chan","year":"2011","journal-title":"Endocr Pract."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"1141-50","DOI":"10.1089\/088922203771881248","article-title":"HIV protease inhibitor ritonavir induces lipoatrophy in male mice.","volume":"19","author":"E Goetzman","year":"2003","journal-title":"AIDS Res Hum Retroviruses."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"513-5","DOI":"10.1586\/17474124.2013.814903","article-title":"Leptin in the treatment of lipodystrophy-associated nonalcoholic fatty liver disease: are we there already?","volume":"7","author":"M Machado","year":"2013","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"74-8","DOI":"10.2174\/1574892811666151111142554","article-title":"Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.","volume":"9","author":"G Akinci","year":"2015","journal-title":"Recent Pat Endocr Metab Immune Drug Discov."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"479-489","DOI":"10.1007\/s12020-018-1589-1","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.","volume":"60","author":"R Brown","year":"2018","journal-title":"Endocrine."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"532-41","DOI":"10.1210\/jc.2006-1546","article-title":"Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.","volume":"92","author":"K Ebihara","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"1101-7","DOI":"10.2337\/dc13-2040","article-title":"Effects of leptin replacement therapy on pancreatic \u03b2-cell function in patients with lipodystrophy.","volume":"37","author":"R Muniyappa","year":"2014","journal-title":"Diabetes Care."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"e0199052","DOI":"10.1371\/journal.pone.0199052","article-title":"Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy.","volume":"13","author":"J Lima","year":"2018","journal-title":"PLoS One."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"203-17","DOI":"10.1007\/s10571-015-0282-7","article-title":"Leptin Dysfunction and Alzheimer's Disease: Evidence from Cellular, Animal, and Human Studies.","volume":"36","author":"M McGuire","year":"2016","journal-title":"Cell Mol Neurobiol."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"3182-9","DOI":"10.2337\/diabetes.54.11.3182","article-title":"Central leptin acutely reverses diet-induced hepatic insulin resistance.","volume":"54","author":"A Pocai","year":"2005","journal-title":"Diabetes."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"1706-12","DOI":"10.2337\/diabetes.48.9.1706","article-title":"Role of the sympathetic nervous system and insulin in enhancing glucose uptake in peripheral tissues after intrahypothalamic injection of leptin in rats.","volume":"48","author":"M Haque","year":"1999","journal-title":"Diabetes."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"287-91","DOI":"10.2337\/diabetes.48.2.287","article-title":"Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats.","volume":"48","author":"Y Minokoshi","year":"1999","journal-title":"Diabetes."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"2757-65","DOI":"10.2337\/db09-0638","article-title":"Distinct effects of leptin and a melanocortin receptor agonist injected into medial hypothalamic nuclei on glucose uptake in peripheral tissues.","volume":"58","author":"C Toda","year":"2009","journal-title":"Diabetes."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"1511-1519","DOI":"10.1210\/jc.2016-3628","article-title":"Effects of Metreleptin in Pediatric Patients With Lipodystrophy.","volume":"102","author":"R Brown","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"3504-3516","DOI":"10.1172\/JCI95476","article-title":"Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.","volume":"128","author":"R Brown","year":"2018","journal-title":"J Clin Invest."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"2009; author reply 2009\u201310","DOI":"10.1056\/NEJM200206203462515","article-title":"Leptin-replacement therapy in lipodystrophy.","volume":"346","author":"A Inui","year":"2002","journal-title":"N Engl J Med."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"1994-2002","DOI":"10.2337\/diabetes.54.7.1994","article-title":"Long-term efficacy of leptin replacement in patients with generalized lipodystrophy.","volume":"54","author":"E Javor","year":"2005","journal-title":"Diabetes."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"2008; author reply 2009-10","DOI":"10.1056\/NEJM200206203462515","article-title":"Leptin-replacement therapy in lipodystrophy.","volume":"346","author":"F Mauvais-Jarvis","year":"2002","journal-title":"N Engl J Med."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"1137-44","DOI":"10.1210\/jc.2008-1588","article-title":"The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia.","volume":"94","author":"K Mulligan","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"2008\u20139; author reply 2009\u201310","DOI":"10.1056\/NEJM200206203462515","article-title":"Leptin-replacement therapy in lipodystrophy.","volume":"346","author":"J Wolfsdorf","year":"2002","journal-title":"N Engl J Med."},{"key":"ref-34","first-page":"2019","article-title":"Myalept FDA US FOOD & DRUG","year":"2014"},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"991-1006","DOI":"10.1161\/CIRCRESAHA.116.305697","article-title":"Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.","volume":"116","author":"J Hall","year":"2015","journal-title":"Circ Res."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"15-21","DOI":"10.1161\/HYPERTENSIONAHA.117.09980","article-title":"Sex Differences in Mechanisms of Hypertension Associated With Obesity.","volume":"71","author":"J Faulkner","year":"2018","journal-title":"Hypertension."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"283-7","DOI":"10.1034\/j.1399-0004.2002.610407.x","article-title":"Cardiomyopathy in congenital complete lipodystrophy.","volume":"61","author":"S Bhayana","year":"2002","journal-title":"Clin Genet."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"245-50","DOI":"10.1097\/MD.0b013e3181e9442f","article-title":"Cardiomyopathy in congenital and acquired generalized lipodystrophy: a clinical assessment.","volume":"89","author":"B Lupsa","year":"2010","journal-title":"Medicine (Baltimore)."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"181-186","DOI":"10.2337\/cd16-0002","article-title":"Cardiac Manifestations of Congenital Generalized Lipodystrophy.","volume":"34","author":"V Sanon","year":"2016","journal-title":"Clin Diabetes."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"202-212","DOI":"10.1016\/j.pathol.2018.11.004","article-title":"Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease.","volume":"51","author":"I Hussain","year":"2019","journal-title":"Pathology."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11883-014-0437-x","article-title":"Congenital lipodystrophies and dyslipidemias.","volume":"16","author":"X Prieur","year":"2014","journal-title":"Curr Atheroscler Rep."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"465-6","DOI":"10.1016\/j.cell.2015.07.007","article-title":"Leptin Does Not Mediate Hypertension Associated With Human Obesity.","volume":"162","author":"R Brown","year":"2015","journal-title":"Cell."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"109-18","DOI":"10.1590\/s0066-782x2010000100017","article-title":"[Cardiometabolic abnormalities in patients with Berardinelli-Seip syndrome].","volume":"94","author":"A R\u00eago","year":"2010","journal-title":"Arq Bras Cardiol."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"53-96","DOI":"10.1016\/B978-0-12-397920-9.00005-6","article-title":"Mouse models of lipodystrophy and their significance in understanding fat regulation.","volume":"109","author":"J Rochford","year":"2014","journal-title":"Curr Top Dev Biol."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"1099-111","DOI":"10.1128\/MCB.06465-11","article-title":"Berardinelli-seip congenital lipodystrophy 2\/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation.","volume":"32","author":"W Chen","year":"2012","journal-title":"Mol Cell Biol."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"17-24","DOI":"10.1016\/j.ddmod.2007.10.003","article-title":"Mouse Models of Lipodystrophy Key reagents for the understanding of the metabolic syndrome.","volume":"4","author":"I Asterholm","year":"2007","journal-title":"Drug Discov Today Dis Models."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"73-6","DOI":"10.1038\/43448","article-title":"Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy.","volume":"401","author":"I Shimomura","year":"1999","journal-title":"Nature."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"2320-31","DOI":"10.2337\/db13-0729","article-title":"Adipose-specific knockout of SEIPIN\/BSCL2 results in progressive lipodystrophy.","volume":"63","author":"L Liu","year":"2014","journal-title":"Diabetes."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"8635-47","DOI":"10.1074\/jbc.M110970200","article-title":"Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities.","volume":"277","author":"B Razani","year":"2002","journal-title":"J Biol Chem."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"18656-61","DOI":"10.1073\/pnas.1314863110","article-title":"Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPAR\u03b3.","volume":"110","author":"F Wang","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"15712-7","DOI":"10.1073\/pnas.2536828100","article-title":"Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle.","volume":"100","author":"W He","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"213-9","DOI":"10.1161\/HYPERTENSIONAHA.115.06954","article-title":"Adipocyte (Pro)Renin-Receptor Deficiency Induces Lipodystrophy, Liver Steatosis and Increases Blood Pressure in Male Mice.","volume":"68","author":"C Wu","year":"2016","journal-title":"Hypertension."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"3182-94","DOI":"10.1101\/gad.12.20.3182","article-title":"Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: Model for congenital generalized lipodystrophy.","volume":"12","author":"I Shimomura","year":"1998","journal-title":"Genes Dev."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"3168-81","DOI":"10.1101\/gad.12.20.3168","article-title":"Life without white fat: A transgenic mouse.","volume":"12","author":"J Moitra","year":"1998","journal-title":"Genes Dev."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"pii: 129781","DOI":"10.1172\/jci.insight.129781","article-title":"Targeting ATGL to rescue BSCL2 lipodystrophy and its associated cardiomyopathy.","volume":"5","author":"H Zhou","year":"2019","journal-title":"JCI Insight."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S1878-6480(17)30427-5","article-title":"The SGLT2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model.","volume":"9","author":"M Joubert","year":"2017","journal-title":"Diabetes."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"880-3","DOI":"10.1038\/47254","article-title":"Dominant negative mutations in human PPAR\u03b3 associated with severe insulin resistance, diabetes mellitus and hypertension.","volume":"402","author":"I Barroso","year":"1999","journal-title":"Nature."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"829-38","DOI":"10.1161\/ATVBAHA.112.300962","article-title":"Peroxisome proliferator-activated receptor-\u03b3 mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.","volume":"33","author":"M Auclair","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"653-63","DOI":"10.1093\/hmg\/ddi480","article-title":"Nuclear lamin A inhibits adipocyte differentiation: Implications for Dunnigan-type familial partial lipodystrophy.","volume":"15","author":"R Boguslavsky","year":"2006","journal-title":"Hum Mol Genet."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"163-5","DOI":"10.1172\/JCI22382","article-title":"Unbuckling lipodystrophy from insulin resistance and hypertension.","volume":"114","author":"R Hegele","year":"2004","journal-title":"J Clin Invest."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"48-54","DOI":"10.1016\/j.cmet.2009.06.003","article-title":"Genetic evidence supporting a critical role of endothelial caveolin-1 during the progression of atherosclerosis.","volume":"10","author":"C Fern\u00e1ndez-Hernando","year":"2009","journal-title":"Cell Metab."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"2449-52","DOI":"10.1126\/science.1062688","article-title":"Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice.","volume":"293","author":"M Drab","year":"2001","journal-title":"Science."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"38121-38","DOI":"10.1074\/jbc.M105408200","article-title":"Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities.","volume":"276","author":"B Razani","year":"2001","journal-title":"J Biol Chem."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"11375-80","DOI":"10.1073\/pnas.172360799","article-title":"Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice.","volume":"99","author":"Y Zhao","year":"2002","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"642-54","DOI":"10.1177\/0300985810383870","article-title":"Pathology of congenital generalized lipodystrophy in Agpat2-\/- mice.","volume":"48","author":"P Vogel","year":"2011","journal-title":"Vet Pathol."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"491-505","DOI":"10.1016\/j.molmet.2016.05.004","article-title":"AGPAT2 is essential for postnatal development and maintenance of white and brown adipose tissue.","volume":"5","author":"K Cautivo","year":"2016","journal-title":"Mol Metab."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"39-45","DOI":"10.1016\/j.bbrc.2015.09.128","article-title":"AGPAT2 deficiency impairs adipogenic differentiation in primary cultured preadipocytes in a non-autophagy or apoptosis dependent mechanism.","volume":"467","author":"M Fern\u00e1ndez-Galilea","year":"2015","journal-title":"Biochem Biophys Res Commun."},{"key":"ref-68","article-title":"Leptin restores endothelial function via endothelial PPARg- Nox1 mediated mechanisms in a mouse model of congenital generalized lipodystrophy.","author":"T Bruder-Nascimento","journal-title":"Hypertension."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"18-23","DOI":"10.1681\/ASN.2009030300","article-title":"The biology of the (pro)renin receptor.","volume":"21","author":"G Nguyen","year":"2010","journal-title":"J Am Soc Nephrol."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"365-72","DOI":"10.1161\/01.HYP.0000255576.16089.b9","article-title":"Elevated blood pressure in transgenic lipoatrophic mice and altered vascular function.","volume":"49","author":"K Takemori","year":"2007","journal-title":"Hypertension."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"8456-60","DOI":"10.1074\/jbc.275.12.8456","article-title":"Mechanism of insulin resistance in A-ZIP\/F-1 fatless mice.","volume":"275","author":"J Kim","year":"2000","journal-title":"J Biol Chem."},{"key":"ref-72","doi-asserted-by":"publisher","first-page":"127-44","DOI":"10.1007\/978-1-4614-1222-9_9","article-title":"Atherosclerosis, caveolae and caveolin-1.","volume":"729","author":"S Pavlides","year":"2012","journal-title":"Adv Exp Med Biol."},{"key":"ref-73","doi-asserted-by":"publisher","first-page":"2373-82","DOI":"10.1084\/jem.20062340","article-title":"Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice.","volume":"204","author":"T Murata","year":"2007","journal-title":"J Exp Med."},{"key":"ref-74","doi-asserted-by":"publisher","first-page":"410-8","DOI":"10.1016\/j.bbalip.2016.02.018","article-title":"Adipose tissue deficiency results in severe hyperlipidemia and atherosclerosis in the low-density lipoprotein receptor knockout mice.","volume":"1861","author":"M Wang","year":"2016","journal-title":"Biochim Biophys Acta."},{"key":"ref-75","doi-asserted-by":"publisher","first-page":"2114-24","DOI":"10.1161\/CIRCULATIONAHA.113.001278","article-title":"Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice.","volume":"127","author":"S Cipriani","year":"2013","journal-title":"Circulation."},{"key":"ref-76","doi-asserted-by":"publisher","first-page":"524-36","DOI":"10.1093\/toxsci\/kfq213","article-title":"Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia.","volume":"117","author":"B Jiang","year":"2010","journal-title":"Toxicol Sci."},{"key":"ref-77","doi-asserted-by":"publisher","first-page":"1453-69","DOI":"10.1111\/j.1476-5381.2010.01147.x","article-title":"Chemokine receptor CCR5: From AIDS to atherosclerosis.","volume":"162","author":"K Jones","year":"2011","journal-title":"Br J Pharmacol."},{"key":"ref-78","doi-asserted-by":"publisher","first-page":"257-62","DOI":"10.1161\/01.cir.104.3.257","article-title":"Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.","volume":"104","author":"J Stein","year":"2001","journal-title":"Circulation."},{"key":"ref-79","doi-asserted-by":"publisher","first-page":"164-71","DOI":"10.1097\/QAI.0000000000000138","article-title":"Increased arterial inflammation relates to high-risk coronary plaque morphology in HIV-infected patients.","volume":"66","author":"A Tawakol","year":"2014","journal-title":"J Acquir Immune Defic Syndr."},{"key":"ref-80","doi-asserted-by":"publisher","first-page":"39-46","DOI":"10.1016\/j.mce.2007.09.012","article-title":"Adrenocortical changes and arterial hypertension in lipoatrophic A-ZIP\/F-1 mice.","volume":"280","author":"V Lamounier-Zepter","year":"2008","journal-title":"Mol Cell Endocrinol."},{"key":"ref-81","doi-asserted-by":"publisher","first-page":"H506-H515","DOI":"10.1152\/ajpheart.00473.2018","article-title":"Losartan prevents the elevation of blood pressure in adipose-PRR deficient female mice while elevated circulating sPRR activates the renin-angiotensin system.","volume":"316","author":"E Gatineau","year":"2019","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"ref-82","doi-asserted-by":"publisher","first-page":"87-111","DOI":"10.1007\/978-3-319-70178-3_6","article-title":"Sex Differences in Leptin Control of Cardiovascular Function in Health and Metabolic Diseases.","volume":"1043","author":"E Belin de Chantem\u00e8le","year":"2017","journal-title":"Adv Exp Med Biol."},{"key":"ref-83","doi-asserted-by":"publisher","first-page":"271-9","DOI":"10.1161\/HYPERTENSIONAHA.110.168427","article-title":"Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice.","volume":"58","author":"E Belin de Chantem\u00e8le","year":"2011","journal-title":"Hypertension."},{"key":"ref-84","doi-asserted-by":"publisher","first-page":"753-63","DOI":"10.1161\/CIRCULATIONAHA.109.853077","article-title":"Protein tyrosine phosphatase 1B, a major regulator of leptin-mediated control of cardiovascular function.","volume":"120","author":"E Belin de Chantem\u00e8le","year":"2009","journal-title":"Circulation."},{"key":"ref-85","doi-asserted-by":"publisher","first-page":"235-44","DOI":"10.1016\/j.phrs.2015.10.012","article-title":"Deletion of protein tyrosine phosphatase 1b in proopiomelanocortin neurons reduces neurogenic control of blood pressure and protects mice from leptin- and sympatho-mediated hypertension.","volume":"102","author":"T Bruder-Nascimento","year":"2015","journal-title":"Pharmacol Res."},{"key":"ref-86","doi-asserted-by":"publisher","first-page":"1949-53","DOI":"10.1097\/00004872-199917121-00026","article-title":"Contrasting blood pressure effects of obesity in leptin-deficient ob\/ob mice and agouti yellow obese mice.","volume":"17","author":"A Mark","year":"1999","journal-title":"J Hypertens."},{"key":"ref-87","doi-asserted-by":"publisher","first-page":"2134-45","DOI":"10.1161\/CIRCULATIONAHA.115.018226","article-title":"Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis.","volume":"132","author":"A Huby","year":"2015","journal-title":"Circulation."},{"key":"ref-88","doi-asserted-by":"publisher","first-page":"1020-8","DOI":"10.1161\/HYPERTENSIONAHA.115.06642","article-title":"Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice.","volume":"67","author":"A Huby","year":"2016","journal-title":"Hypertension."},{"key":"ref-89","doi-asserted-by":"publisher","first-page":"1324-31","DOI":"10.1161\/01.HYP.0000128019.19363.f9","article-title":"Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis study.","volume":"43","author":"M Saad","year":"2004","journal-title":"Hypertension."},{"key":"ref-90","doi-asserted-by":"publisher","first-page":"1719-27","DOI":"10.1161\/CIRCULATIONAHA.105.535039","article-title":"Relations of insulin sensitivity to longitudinal blood pressure tracking: Variations with baseline age, body mass index, and blood pressure.","volume":"112","author":"J Arnl\u00f6v","year":"2005","journal-title":"Circulation."},{"key":"ref-91","doi-asserted-by":"publisher","first-page":"119-25","DOI":"10.1007\/s11906-002-0036-z","article-title":"Cardiovascular and sympathetic effects of leptin.","volume":"4","author":"K Rahmouni","year":"2002","journal-title":"Curr Hypertens Rep."},{"key":"ref-92","doi-asserted-by":"publisher","first-page":"168-73","DOI":"10.2337\/diabetes.51.1.168","article-title":"Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway.","volume":"51","author":"C Vecchione","year":"2002","journal-title":"Diabetes."},{"key":"ref-93","doi-asserted-by":"publisher","first-page":"1605-12","DOI":"10.1161\/ATVBAHA.112.251140","article-title":"Leptin potentiates endothelium-dependent relaxation by Inducing endothelial expression of neuronal NO synthase.","volume":"32","author":"S Benkhoff","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"ref-94","doi-asserted-by":"publisher","first-page":"1683-97","DOI":"10.1161\/ATVBAHA.117.309798","article-title":"Selective Deletion of Leptin Signaling in Endothelial Cells Enhances Neointima Formation and Phenocopies the Vascular Effects of Diet-Induced Obesity in Mice.","volume":"37","author":"A Hubert","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"ref-95","doi-asserted-by":"publisher","first-page":"277-9","DOI":"10.1161\/01.RES.0000089255.37804.72","article-title":"The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes.","volume":"93","author":"V Rajapurohitam","year":"2003","journal-title":"Circ Res."},{"key":"ref-96","doi-asserted-by":"publisher","first-page":"114-20","DOI":"10.1016\/s0895-7061(00)01241-3","article-title":"Plasma leptin concentration, insulin sensitivity, and 24-hour ambulatory blood pressure and left ventricular geometry.","volume":"14","author":"G Paolisso","year":"2001","journal-title":"Am J Hypertens."},{"key":"ref-97","doi-asserted-by":"publisher","first-page":"511-24","DOI":"10.4330\/wjc.v7.i9.511","article-title":"Lean heart: Role of leptin in cardiac hypertrophy and metabolism.","volume":"7","author":"M Hall","year":"2015","journal-title":"World J Cardiol."},{"key":"ref-98","doi-asserted-by":"publisher","first-page":"770-84","DOI":"10.1016\/j.cmet.2016.04.011","article-title":"Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk.","volume":"23","author":"J Stern","year":"2016","journal-title":"Cell Metab."},{"key":"ref-99","doi-asserted-by":"publisher","first-page":"275-279","DOI":"10.1016\/j.diabet.2016.08.004","article-title":"One-year metreleptin therapy decreases PCSK9 serum levels in diabetic patients with monogenic lipodystrophy syndromes.","volume":"43","author":"C Vatier","year":"2017","journal-title":"Diabetes Metab."},{"key":"ref-100","doi-asserted-by":"publisher","first-page":"14564-8","DOI":"10.1073\/pnas.93.25.14564","article-title":"Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells.","volume":"93","author":"T Gainsford","year":"1996","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-101","doi-asserted-by":"publisher","first-page":"137-49","DOI":"10.1111\/cen.12980","article-title":"Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.","volume":"85","author":"J Chan","year":"2016","journal-title":"Clin Endocrinol (Oxf)."},{"key":"ref-102","article-title":"Myalepta (metreleptin) 3, 5.8 and 11.3 mg powder for solution for injection: EU summary of product characteristics","author":"W Ltd","year":"2018"}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/8-1756\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-1756\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-1756\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T13:10:13Z","timestamp":1694005813000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/8-1756\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":102,"URL":"https:\/\/doi.org\/10.12688\/f1000research.20150.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.22135.r54856","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.22135.r54857","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.22135.r54858","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/8-1756\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.22135.r54856, Jussara do Carmo, Department of Physiology and Biophysics, University of Mississippi Medical Center, Mississippi, 16 Oct 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1756\/v1#referee-response-54856","order":0,"name":"referee-response-54856","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.22135.r54858, Frederique Yiannikouris, Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, 16 Oct 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1756\/v1#referee-response-54858","order":1,"name":"referee-response-54858","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.22135.r54857, Xavier Prieur, L'Institut du Thorax, INSERM, CNRS, Universit\u00e9 de Nantes, Nantes, 16 Oct 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1756\/v1#referee-response-54857","order":2,"name":"referee-response-54857","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This work was supported by an Established Investigator Award from the American Heart Association (19EIA34760167, to EB), a K99\/R00 (1K99HL140139-01A1 and 4R00HL140139-03 to TBN) and R01s (1R01HL130301-01; 1R01HL147639-01A1 to EB) from the National Heart, Lung, and Blood Institute (NHLBI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}